title: Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection.
abstract: Retroperitoneal lymph node dissection (RPLND) is a critical aspect of staging and treatment of nonseminomatous germ cell tumors (NSGCTs) of the testis. RPLND achieves cure in a majority of patients with low-volume metastatic disease and minimizes the need for chemotherapy. Initial surgical approaches to RPLND, involving wide limits to dissection, were associated with high rates of retrograde ejaculation and significant overall morbidity. Evolving modified RPLND templates helped reduce rates of retrograde ejaculation but may be associated with a 3 %-23 % risk of unresected metastasis. Modified templates have become a standard of care in primary RPLND with low-volume metastatic disease. Only highly select patients at specialized centers should undergo modified template RPLND in the postchemotherapy setting, because risks of unresected disease are higher than in the primary setting. Bilateral RPLND optimizes cancer control and can preserve antegrade ejaculation if nerve sparing is performed. We also briefly discuss minimally invasive approaches to RPLND.
authors.affiliation: University of Chicago, Section of Urology, 5841 S. Maryland Avenue, MC6038, Chicago, IL, 60637, USA, shane.pearce@uchospitals.edu.
authors.forename: Shane
authors.initials: S
authors.lastname: Pearce
authors.forename: Zoe
authors.initials: Z
authors.lastname: Steinberg
authors.forename: Scott
authors.initials: S
authors.lastname: Eggener
mesh_terms: D004867:Equipment Design; D006801:Humans; D008197:Lymph Node Excision / Q000295:instrumentation*; D008198:Lymph Nodes / Q000601:surgery*; D008207:Lymphatic Metastasis; D008297:Male; D019060:Minimally Invasive Surgical Procedures / Q000295:instrumentation*; D009373:Neoplasms, Germ Cell and Embryonal / Q000556:secondary / Q000601:surgery*; D009919:Orchiectomy / Q000379:methods*; D012187:Retroperitoneal Space; D013736:Testicular Neoplasms / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome
references.citation: J Clin Oncol. 2007 Mar 20;25(9):1033-7
references.pmid: 17261854
references.citation: J Urol. 1993 Jun;149(6):1472-4
references.pmid: 8388961
references.citation: Eur Urol. 2008 Nov;54(5):1004-15
references.pmid: 18722704
references.citation: J Urol. 1988 Jun;139(6):1220-4
references.pmid: 2836633
references.citation: World J Urol. 2008 Dec;26(6):561-9
references.pmid: 18594824
references.citation: Urol Clin North Am. 1977 Oct;4(3):509-21
references.pmid: 610039
references.citation: BJU Int. 2009 Nov;104(9 Pt B):1362-8
references.pmid: 19840014
references.citation: J Urol. 1987 Jul;138(1):77-82
references.pmid: 3599225
references.citation: J Urol. 1995 Mar;153(3 Pt 2):976-80
references.pmid: 7853586
references.citation: J Urol. 1996 Nov;156(5):1656-8
references.pmid: 8863564
references.citation: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references.pmid: 17237035
references.citation: Semin Urol. 1984 Nov;2(4):264-74
references.pmid: 6505449
references.citation: Urology. 2009 Feb;73(2):328-31; discussion 331-2
references.pmid: 19022490
references.citation: Urology. 2007 Dec;70(6):1168-72
references.pmid: 18158040
references.citation: J Urol. 1985 Sep;134(3):485-9
references.pmid: 2993672
references.citation: J Urol. 1990 Nov;144(5):1160-3
references.pmid: 2172569
references.citation: Nat Clin Pract Urol. 2005 Jul;2(7):330-5
references.pmid: 16474785
references.citation: J Urol. 1990 Aug;144(2 Pt 1):287-91; discussion 291-2
references.pmid: 2165181
references.citation: Cancer. 2007 Sep 15;110(6):1235-40
references.pmid: 17665498
references.citation: J Natl Compr Canc Netw. 2006 Nov;4(10):1059-70
references.pmid: 17112453
references.citation: J Urol. 1982 Aug;128(2):315-20
references.pmid: 7109099
references.citation: J Urol. 2000 Jun;163(6):1793-6
references.pmid: 10799184
references.citation: J Urol. 2007 Mar;177(3):937-42; discussion 942-3
references.pmid: 17296380
references.citation: J Urol. 1994 Aug;152(2 Pt 1):424-7
references.pmid: 8015086
references.citation: J Clin Oncol. 2008 Dec 1;26(34):5524-9
references.pmid: 18936477
references.citation: Urol Oncol. 2003 Mar-Apr;21(2):129-32
references.pmid: 12856641
references.citation: Urology. 1994 Jul;44(1):2-14
references.pmid: 7518979
references.citation: J Urol. 1963 Jan;89:106-10
references.pmid: 14017271
references.citation: J Urol. 2012 Feb;187(2):487-92
references.pmid: 22177913
references.citation: J Clin Oncol. 2007 Oct 1;25(28):4365-9
references.pmid: 17906201
references.citation: Cancer. 1974 Feb;33(2):340-8
references.pmid: 4855872
references.citation: J Urol. 1993 Feb;149(2):237-43
references.pmid: 8381190
references.citation: Eur Urol. 1990;17(2):97-106
references.pmid: 2155791
references.citation: J Urol. 1971 Jul;106(1):84-93
references.pmid: 5105689
references.citation: J Clin Oncol. 2003 Sep 1;21(17):3310-7
references.pmid: 12947067
references.citation: BJU Int. 2008 Aug;102(3):310-4
references.pmid: 18325053
references.citation: J Clin Oncol. 2005 Apr 20;23(12):2781-8
references.pmid: 15837993
references.citation: J Clin Oncol. 1997 Apr;15(4):1455-64
references.pmid: 9193340
references.citation: J Urol. 2009 Feb;181(2):627-32; discussion 632-3
references.pmid: 19091344
references.citation: J Am Med Assoc. 1959 Dec 19;171:2194-8
references.pmid: 14430944
references.citation: Ann Surg. 1902 Oct;36(4):539-49
references.pmid: 17861190